Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Schizophrenia shows a unique metabolomics signature in plasma.

He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D.

Transl Psychiatry. 2012 Aug 14;2:e149. doi: 10.1038/tp.2012.76.

2.

Metabolomic analysis of human plasma reveals that arginine is depleted in knee osteoarthritis patients.

Zhang W, Sun G, Likhodii S, Liu M, Aref-Eshghi E, Harper PE, Martin G, Furey A, Green R, Randell E, Rahman P, Zhai G.

Osteoarthritis Cartilage. 2016 May;24(5):827-34. doi: 10.1016/j.joca.2015.12.004. Epub 2015 Dec 18.

3.

GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells.

Liu ML, Zheng P, Liu Z, Xu Y, Mu J, Guo J, Huang T, Meng HQ, Xie P.

Mol Biosyst. 2014 Jul 29;10(9):2398-406. doi: 10.1039/c4mb00157e.

PMID:
24975926
4.

Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia.

Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, Takeda M, Kunugi H, Itakura M, Ohmori T.

Neurosci Lett. 2007 Mar 19;415(1):28-33. Epub 2007 Jan 11.

PMID:
17287082
5.

Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone.

Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS.

J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26.

PMID:
22800120
6.

Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.

Liang Q, Wang C, Li B.

Appl Biochem Biotechnol. 2015 Aug;176(8):2170-84. doi: 10.1007/s12010-015-1706-z. Epub 2015 Jun 19.

PMID:
26088916
7.

Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.

Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, Wang Y, Deng YL, Ren RJ, Xu W, Ma JF, Zhang YN, Zhao AH, Chen SD, Jia W.

J Proteome Res. 2014 May 2;13(5):2649-58. doi: 10.1021/pr5000895. Epub 2014 Apr 14.

PMID:
24694177
8.

Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design.

Cao B, Jin M, Brietzke E, McIntyre RS, Wang D, Rosenblat JD, Ragguett RM, Zhang C, Sun X, Rong C, Wang J.

Psychiatry Clin Neurosci. 2019 Mar;73(3):100-108. doi: 10.1111/pcn.12779. Epub 2018 Oct 8.

PMID:
30156046
9.

Association analysis of glycine- and serine-related genes in a Japanese population of patients with schizophrenia.

Ohnuma T, Shibata N, Maeshima H, Baba H, Hatano T, Hanzawa R, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):511-8. doi: 10.1016/j.pnpbp.2009.02.004. Epub 2009 Feb 14.

PMID:
19223009
10.

Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.

Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L.

J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov 8.

PMID:
22007635
11.

Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy.

Alexander D, Lombardi R, Rodriguez G, Mitchell MM, Marian AJ.

Eur J Clin Invest. 2011 May;41(5):527-38. doi: 10.1111/j.1365-2362.2010.02441.x. Epub 2010 Dec 14.

12.

LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease.

Benito S, Sánchez A, Unceta N, Andrade F, Aldámiz-Echevarria L, Goicolea MA, Barrio RJ.

Anal Bioanal Chem. 2016 Jan;408(3):747-60. doi: 10.1007/s00216-015-9153-9. Epub 2015 Nov 4.

PMID:
26537926
13.

Identification of metabolic markers in coronary artery disease using an untargeted LC-MS based metabolomic approach.

Basak T, Varshney S, Hamid Z, Ghosh S, Seth S, Sengupta S.

J Proteomics. 2015 Sep 8;127(Pt A):169-77. doi: 10.1016/j.jprot.2015.03.011. Epub 2015 Mar 17.

PMID:
25790721
14.

Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study.

Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, Rosenblat JD, Zuckerman H, Liu Y, Xie Q, Wang J.

Amino Acids. 2018 Aug;50(8):1013-1023. doi: 10.1007/s00726-018-2579-6. Epub 2018 May 23.

PMID:
29796929
15.

Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome.

Paredes RM, Quinones M, Marballi K, Gao X, Valdez C, Ahuja SS, Velligan D, Walss-Bass C.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1139-48. doi: 10.1017/S1461145714000157. Epub 2014 Feb 25.

PMID:
24565079
16.

Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis.

Tasic L, Pontes JGM, Carvalho MS, Cruz G, Dal Mas C, Sethi S, Pedrini M, Rizzo LB, Zeni-Graiff M, Asevedo E, Lacerda ALT, Bressan RA, Poppi RJ, Brietzke E, Hayashi MAF.

Schizophr Res. 2017 Jul;185:182-189. doi: 10.1016/j.schres.2016.12.024. Epub 2016 Dec 29.

PMID:
28040324
17.

Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study.

Liu ML, Zhang XT, Du XY, Fang Z, Liu Z, Xu Y, Zheng P, Xu XJ, Cheng PF, Huang T, Bai SJ, Zhao LB, Qi ZG, Shao WH, Xie P.

J Transl Med. 2015 Jul 14;13:226. doi: 10.1186/s12967-015-0540-y.

18.

Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis.

Jung J, Kim SH, Lee HS, Choi GS, Jung YS, Ryu DH, Park HS, Hwang GS.

Clin Exp Allergy. 2013 Apr;43(4):425-33. doi: 10.1111/cea.12089.

PMID:
23517038
19.

Increased alpha-defensins as a blood marker for schizophrenia susceptibility.

Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M, Bahn S.

Mol Cell Proteomics. 2008 Jul;7(7):1204-13. doi: 10.1074/mcp.M700459-MCP200. Epub 2008 Mar 18.

20.

Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.

Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M.

Neurosci Lett. 2014 Oct 17;582:93-8. doi: 10.1016/j.neulet.2014.08.052. Epub 2014 Sep 10.

PMID:
25218715

Supplemental Content

Support Center